Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Finding and Phase II Study of Selumetinib (AZD6244) (Hyd-Sulfate) in Combination With Irinotecan, in 2nd Line Patients With K-ras or B-raf Mutation Positive Advanced or Metastatic Colorectal Cancer

NCT01116271 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01116271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01116271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Finding and Phase II Study of Selumetinib (AZD6244) (Hyd-Sulfate) in Combination With Irinotecan, in 2nd Line Patients With K-ras or B-raf Mutation Positive Advanced or Metastatic Colorectal Cancer
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2010
Completion date
July 31, 2012
Enrollment
32 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer